Cadd4 effectively reduces cholesterol levels without side effects.
4 citations
,
March 2008 in “Journal of the American Academy of Dermatology” 5 citations
,
December 2015 in “PubMed” Some gonadal hormone drugs can block filovirus entry into cells.
April 2026 in “Journal of Cancer” Cepharanthine shows promise as a natural anticancer treatment.
341 citations
,
November 2009 in “The FASEB Journal” Calreticulin has roles in healing, immune response, and disease beyond its known functions in the endoplasmic reticulum.
31 citations
,
July 2004 in “Molecular Medicine” Certain defective glucocorticoid receptor mutants move faster inside cell nuclei and work less effectively.
12 citations
,
March 2017 in “Medicinal Chemistry Research” Some curcumin-like compounds can effectively and safely block the enzyme linked to hair loss and other conditions related to male hormones.
7 citations
,
March 2023 in “Arabian Journal of Chemistry” Cepharanthine may help treat COVID-19 by targeting multiple pathways.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
12 citations
,
June 2019 in “Psychoneuroendocrinology” Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
28 citations
,
May 1986 in “Clinics in endocrinology and metabolism” New compounds may soon be tested to treat excessive hair growth in women.
119 citations
,
June 2005 in “Journal of Molecular and Cellular Cardiology” Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.
4 citations
,
March 2018 in “Journal of labelled compounds & radiopharmaceuticals” A new compound was effective for imaging prostate cancer in rats.
39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
88 citations
,
August 2019 in “Nature communications” Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
18 citations
,
March 2010 in “Gynecologic and obstetric investigation” The oral contraceptive alone is the preferred treatment for hirsutism, as adding the GnRH analog showed no significant benefit.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
6 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
5 citations
,
May 2020 in “Clinical Phytoscience” Cuscuta reflexa leaves extract may help lower blood sugar and improve diabetes symptoms.
5 citations
,
January 2022 in “Clinical cancer investigation journal” Certain Dibenzo derivatives may help treat prostate cancer.
6 citations
,
January 2018 in “Pharmacoepidemiology and Drug Safety” Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
15 citations
,
November 2002 in “Cardiology in Review” Cardiovascular drugs can cause various skin problems, so recognizing these reactions is important.
6 citations
,
January 2025 in “RSC Medicinal Chemistry” Targeting the RAAS with small molecules can improve cardiovascular disease treatments.
2 citations
,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
June 2026 in “Dermatology and Therapy” In the first 10 months following its FDA approval in June 2023, ritlecitinib was prescribed to a diverse group of patients aged ≥12 years with severe alopecia areata (AA) in the USA. This study analyzed data from 2,562 patients in cohort 1 and 381 in cohort 2, revealing that 62% were prescribed ritlecitinib by dermatologists, 59% were female, and 35% were adolescents. Approximately 24% had severe AA forms like alopecia totalis or universalis, 12% had other autoimmune disorders, 24% had atopic disorders, and 24% had mental health conditions. Before starting ritlecitinib, 27% had no prior AA treatments, while about one-third received systemic immunomodulators or injectable corticosteroids. In cohort 2, 77% experienced ≥50% scalp hair loss. The findings suggest ritlecitinib offers new opportunities for engaging patients in AA care, regardless of their treatment history or comorbidities.
9 citations
,
July 2002 in “Journal of the European Academy of Dermatology and Venereology” The document concludes that fexofenadine reduces inflammation in chronic hives, cholestyramine helps half of pregnant women with itchy rashes, and relaxing incisions are a good alternative in facial surgery for the elderly.
May 2023 in “Blood cancer discovery” Finasteride reduces AML cell growth by inhibiting androgen receptors.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.